The tp53 genotype but not immunohistochemical result is predictive of response to cisplatin-based neoadjuvant therapy in stage III non–small cell lung cancer
- 30 April 1999
- journal article
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 117 (4) , 744-750
- https://doi.org/10.1016/s0022-5223(99)70295-3
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Structure and Function of the p53 Tumor Suppressor Gene: Clues for Rational Cancer Therapeutic StrategiesJNCI Journal of the National Cancer Institute, 1996
- Improved Survival in Stage III Non-Small-Cell Lung Cancer: Seven-Year Follow-up of Cancer and Leukemia Group B (CALGB) 8433 TrialJNCI Journal of the National Cancer Institute, 1996
- The p53 Gene in Breast Cancer: Prognostic Value of Complementary DNA Sequencing Versus ImmunohistochemistryJNCI Journal of the National Cancer Institute, 1996
- A Randomized Trial Comparing Perioperative Chemotherapy and Surgery With Surgery Alone in Resectable Stage IIIA Non-Small-Cell Lung CancerJNCI Journal of the National Cancer Institute, 1994
- A Randomized Trial Comparing Preoperative Chemotherapy Plus Surgery with Surgery Alone in Patients with Non-Small-Cell Lung CancerNew England Journal of Medicine, 1994
- p53-dependent apoptosis modulates the cytotoxicity of anticancer agentsCell, 1993
- p53 is required for radiation-induced apoptosis in mouse thymocytesNature, 1993
- P53 in tumour pathology: Can we trust immunocytochemistry?The Journal of Pathology, 1992
- Asymptotically Efficient Rank Invariant Test ProceduresJournal of the Royal Statistical Society. Series A (General), 1972
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958